This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

EMC, Jazz Pharma: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.


Amyris (AMRS) upgraded at Morgan Stanley from Equal-weight to Overweight. $32 price target. Company continues to execute on its growth strategy.

Cameron International (CAM) upgraded at Credit Suisse from Neutral to Outperform. $73 price target. Very strong orders.

EMC (EMC - Get Report) upgraded at Oppenheimer from Perform to Outperform. $32 price target. Stock is attractive, following a recent pullback.

East West Bancorp (EWBC - Get Report) upgraded at FBR from Market Perform to Outperform. $23 price target. Stock is attractively valued, following a recent pullback.

Exelon (EXC - Get Report) upgraded at UBS from Neutral to Buy. $50 price target. Cost synergy story and leverage to power recovery.

Jazz Pharmaceuticals (JAZZ - Get Report) upgraded at Jefferies to Buy. $52 price target. Estimates also upped, given recent Xyrem growth.

Oceaneering International (OII) downgraded at Credit Suisse from Outperform to Neutral. $48 price target. Central theses played out.

Oil States (OIS) upgraded at Credit Suisse from Neutral to Outperform. $110 price target. Stock should continue to deliver higher earnings.

Rockwell Automation (ROK) upgraded at Baird from Neutral to Outperform. $92 price target. Company can continue to deliver solid growth over the coming years.

RadioShack (RSH) upgraded at Goldman from Neutral to Buy. Company was also added to the Conviction Buy list. $18 price target. Company is improving its position in the wireless market.

Vanguard Health (VHS) rated new Overweight at JP Morgan. $22 price target. Company has attractive exposure to urban markets.

Vodafone (VOD) upgraded at UBS from Neutral to Buy. $31.05 price target. VZW dividend larger than expected.

Vertex Pharmaceuticals (VRTX - Get Report) upgraded at Citigroup from Hold to Buy. $60 price target. Incivek should not disappoint.

End of report.
This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
VHS $0.00 0.00%
EMC $24.20 -1.40%
EWBC $29.71 -4.00%
EXC $32.39 -1.60%
JAZZ $113.99 -6.40%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs